Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 ?m to about 1000 ?m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 ?m to about 1000 ?m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 ?m to about 1000 ?m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 ?m to about 1000 ?m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 ?m to about 1000 ?m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

Abstract: A system and method of tracking a trailer is provided. The system sends location requests and in response receives the location of the trailer. If the trailer is outside of a virtual fence, it generates an alert.

Abstract: A computer program product includes instructions for causing a processor to: alert a client of the configuration of said computer program product; use a memory space for buffering the network application data destined for the client; release the network application data to the client, based on at least one occurrence of a specified condition that promotes energy savings; and purposely delay at least some of said data with an amount of time greater than zero to promote energy savings.

Abstract: A wheel hub having pilots to guide the installation of a braking device on the wheel hub, wherein the pilots are provided with guide surfaces that are made of a different material than the wheel hub.

Abstract: A method of making an oxide compound, comprising subjecting a base material to a source of heat that produces a localized temperature in the range of 2,000 to 5,500 degrees Celsius that vaporizes the base material which is drawn upward above the surface of the base material where it oxidizes, after which the resulting oxide compound is collected. A method of making bismuth trioxide, comprising providing an electric arc between electrodes, wherein elemental bismuth is in touching proximity to one of the electrodes. The bismuth is evaporated, drawn upward off the surface of the molten metal, forms the bismuth oxide on contact with oxygen, and the particles of bismuth oxide are collected. A method of making an oxide using an electric arc to evaporate a base material which then reacts with oxygen, and collecting the resulting oxides of base material.

Abstract: An apparatus which reduces energy consumption in a wireless client interface by decreasing the amount of time the wireless client interface spends in the awake state and which increases the amount of time it spends in the sleep state. The apparatus comprises: at least one processor for running software configured to communicate with at least one wireless client. The software is configured to: alert the wireless client of the configuration of the apparatus; use a memory space for buffering network application data destined for the wireless client; and release the network application data to the wireless client, based on at least one occurrence of a specified condition that promotes energy savings.

Abstract: A method of making an oxide compound, comprising subjecting a base material to a source of heat that produces a localized temperature in the range of 2,000 to 5,500 degrees Celsius that vaporizes the base material which is drawn upward above the surface of the base material where it oxidizes, after which the resulting oxide compound is collected. A method of making bismuth trioxide, comprising providing an electric arc between electrodes, wherein elemental bismuth is in touching proximity to one of the electrodes. The bismuth is evaporated, drawn upward off the surface of the molten metal, forms the bismuth oxide on contact with oxygen, and the particles of bismuth oxide are collected. A method of making an oxide using an electric arc to evaporate a base material which then reacts with oxygen, and collecting the resulting oxides of base material.

Abstract: A telephone network and a method and system for its use is disclosed. In a first aspect of the present invention, a telephone network is disclosed. The telephone network includes an internet service provider (ISP) coupled to a local switching exchange. The local switching exchange receives and transmits calls to a plurality of devices. The network includes a plurality of modems coupled to the ISP. The network also includes a plurality of phone systems. Each of the phone systems including a cordless unit and a base station. Each of the plurality of phone systems also is associated with one of the plurality of modems, wherein a call can be routed to or from each of the cordless units through any of the modems to any of the plurality of devices. In a second aspect, a method and system for sending a call from a phone system to a device is disclosed. The phone system comprises a cordless unit and a base station. The phone system is also coupled to a modem.

Abstract: A spatial light modulator (10) having a micromechanical active portion (12) encompassed by a light shield (14). The light shield (14) is fabricated upon a substrate (36) and has a plurality of openings (72, and 80) to permit underlying layers of photoresist (90, 92) to be undercut from beneath the light shield. Removal of the photoresist layers provides a sufficiently flat light shield, and eliminates the possibility that particles from the photoresist layer could migrate to beneath active micromirrors (30) of the spatial light modulator (12).

Abstract: A brake drum for mounting on a wheel hub has first and second drum pilots for facilitating proper alignment when installing the brake drum on the hub. The first drum pilot is configured to engage a first hub pilot and the second drum pilot is configured to engage a second hub pilot. When the brake drum is initially moved toward the hub during installation, the first drum pilot engages the first hub pilot and the second drum pilot is sufficiently spaced away from the first hub pilot to prevent the front edge of the second drum pilot from being caught on the corner edge of the second hub pilot and the drum becoming eccentrically mounted.

Abstract: A ring loader device is used for expanding an elastic cincture band prior to application to a user's male sex organ for cincturing an engorged condition thereof as a treatment for impotence. A cone component has a conical shaped pyramid with vertical grooves. A corresponding dome component has matable ribs which are received in the cone grooves. The ribs enter the grooves and align the cone and dome as they are matably pressed together. As a prior step, a suitable elastic ring is placed over the tapered smaller end of the cone component, and becomes expanded against the cone outer surface as the dome is pressed onto the cone. The cone may include particular surface contours for corresponding receipt of inside diameter features of the elastic ring, such as a urethra channel or radially inward points for added cincturing pressure. The cone and dome arrangement may be used to expand and align an elastic ring onto a transfer collar, or directly onto the outside diameter of a vacuum chamber.

Abstract: Conjugates comprising bFGF or other FGF polypeptides and a cytotoxic agent are prepared. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, which is attached to bFGF through a chemical bond, or the composition can be prepared as a recombinant DNA chimera. The conjugates are used to specifically target cells, in vivo and in vitro, which express FGF receptors. The cytotoxicity of the conjugates is proportional to the number of receptors expressed by a cell type. The conjugate is useful to effectively treat mammals, and in particular human patients, afflicted with tumorigenic conditions, such as human melanomas, human ovarian carcinomas, teratocarcinomas and neuroblastomas, and other FGF-mediated tumors caused by a proliferation of cells which express FGF receptors.